surpass 5 tirzepatide Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial 💊 Tirzepatide — Mechanism of

, & Kim, Y

Ozempic led to an average loss of up to 4.7 kg (about 10 lbs) over 30 weeks, based on clinical trial comparisons

CJC no DAC GHRH analog stimulating natural growth hormone production

1 GLP-1 RA=glucagon-like peptide-1 receptor agonist Victoza efficacy and safety data for patients with type 2 diabetes Interested in CV outcomes for patients also with established cardiovascular disease

The FTO gene variant (rs9939609) influences not just hunger but also circadian rhythm sensitivity, meaning some patients benefit more dramatically from GLP-1's sleep-regulating effects while others experience a gentler transition